Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Novavax Inc Stock Research

NVAX

7.19USD+0.08(+1.13%)Market Closed
Watchlist

Market Summary

USD7.19+0.08
Market Closed
1.13%

NVAX Alerts

NVAX Stock Price

NVAX RSI Chart

NVAX Valuation

Market Cap

678.1M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

0.42

EV/EBITDA

-0.32

Price/Free Cashflow

-1.04

NVAX Price/Sales (Trailing)

NVAX Profitability

Operating Margin

53.50%

EBT Margin

-58.15%

Return on Equity

103.76%

Return on Assets

-74.89%

Free Cashflow Yield

-96.46%

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

128.28%

Revenue Q/Q

424.3%

NVAX Earnings

Earnings (TTM)

-586.8M

Earnings Y/Y

111.36%

Earnings Q/Q

119.74%

Price Action

52 Week Range

5.6825.66
(Low)(High)

Last 7 days

2.0%

Last 30 days

-13.9%

Last 90 days

-5.3%

Trailing 12 Months

-64.1%

NVAX Financial Health

Current Ratio

0.51

NVAX Investor Care

Shares Dilution (1Y)

20.69%

Diluted EPS (TTM)

-5.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for NVAX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-16
Dubovsky Filip
acquired
97,485
7.71
12,644
president, r&d
2023-09-16
Dubovsky Filip
sold (taxes)
-47,092
7.71
-6,108
president, r&d
2023-08-19
Trizzino John
sold (taxes)
-2,263
7.14
-317
evp, cco and cbo
2023-08-19
Trizzino John
acquired
-
-
655
evp, cco and cbo
2023-08-16
Kelly James Patrick
sold (taxes)
-8,149
7.13
-1,143
evp, cfo and treasurer
2023-08-16
Kelly James Patrick
acquired
-
-
2,366
evp, cfo and treasurer
2023-06-25
Trizzino John
sold (taxes)
-2,700
6.7
-403
evp, cco and cbo
2023-06-25
Trizzino John
acquired
-
-
833
evp, cco and cbo
2023-06-25
Herrmann John A III
acquired
-
-
833
evp, chief legal officer
2023-06-25
Herrmann John A III
sold (taxes)
-1,862
6.7
-278
evp, chief legal officer

1–10 of 50

Which funds bought or sold NVAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
1,274
1,274
-%
2023-09-20
BARCLAYS PLC
added
15.73
780,000
4,023,000
-%
2023-09-12
Farther Finance Advisors, LLC
reduced
-16.67
-9.00
74.00
-%
2023-08-22
Asset Dedication, LLC
unchanged
-
-
-
-%
2023-08-22
COMERICA BANK
new
-
-
-
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
55.79
381,344
950,297
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
added
18.53
120,875
564,727
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
3.66
78,002
778,486
-%
2023-08-16
Sunbelt Securities, Inc.
unchanged
-
8.00
74.00
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-16.95
-229,667
1,868,330
-%

1–10 of 36

Latest Funds Activity

Are funds buying NVAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVAX
No. of Funds

Schedule 13G FIlings of Novavax

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 18, 2023
sk bioscience co., ltd.
6.4%
6,500,000
SC 13G
May 10, 2023
state street corp
12.11%
10,452,512
SC 13G/A
Apr 27, 2023
shah capital management
5.28%
4,550,756
SC 13D
Feb 09, 2023
vanguard group inc
10.41%
8,844,653
SC 13G/A
Feb 02, 2023
state street corp
7.15%
6,076,518
SC 13G/A
Feb 01, 2023
blackrock inc.
5.7%
4,808,261
SC 13G/A
Mar 11, 2022
blackrock inc.
5.8%
4,410,761
SC 13G/A
Feb 14, 2022
ra capital management, l.p.
2.8%
2,097,794
SC 13G/A
Feb 08, 2022
blackrock inc.
5.8%
4,410,761
SC 13G
Feb 16, 2021
ra capital management, l.p.
6.0%
3,788,564
SC 13G

Recent SEC filings of Novavax

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
SC 13G
Major Ownership Report
Aug 08, 2023
S-8
Employee Benefits Plan
Aug 08, 2023
10-Q
Quarterly Report
Aug 08, 2023
424B5
Prospectus Filed
Aug 08, 2023
8-K
Current Report
Aug 08, 2023
8-K
Current Report
Aug 08, 2023
8-K
Current Report

NVAX Fair Value

Loading...

Peers (Alternatives to Novavax)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.9B
26.6B
4.85% 20.90%
18.03
5.41
0.75% 21.34%
94.2B
27.4B
-1.93% 22.79%
17.18
3.44
-0.48% 32.56%
37.9B
10.7B
-12.64% -18.65%
31.39
3.56
-53.67% -91.41%
37.3B
10.0B
-2.84% 30.20%
13.98
3.74
-6.23% 29.40%
MID-CAP
11.3B
1.7B
8.03% 13.91%
63.88
6.74
29.01% 1345.90%
4.3B
-
-8.13% 165.26%
-7.28
48.33
54.84% -12.96%
3.0B
-
-5.45% -21.11%
-23.04
37.44
122.90% 54.78%
1.9B
80.2M
3.54% -49.89%
-5.78
23.59
42.17% -39.82%
SMALL-CAP
1.4B
121.2M
-13.83% -27.58%
-4.86
11.52
-70.36% -531.73%
979.0M
15.3M
-20.35% -0.54%
-5.39
63.94
1090.59% -36.57%
678.1M
1.6B
-13.89% -64.12%
-1.16
0.42
23.74% 60.24%
206.9M
-
-21.05% -90.40%
-0.98
1.51
116.83% 16.61%
109.6M
2.1M
-12.14% -66.77%
-1.09
53.32
487.70% -8.66%
104.5M
-
-28.14% -88.04%
-0.53
0.43
113.96% -15.19%
3.6M
-
-8.13% -96.28%
-0.05
3.21
- -129.46%

Novavax News

MarketWatch
Novavax Inc. stock outperforms competitors on strong trading day.
MarketWatch,
5 hours ago
Seeking Alpha
Investor's Business Daily
The Motley Fool
InvestorsObserver
The Motley Fool
Investor's Business Daily
The Motley Fool
The Motley Fool

Returns for NVAX

Cumulative Returns on NVAX

-19.6%


10-Year Cumulative Returns

-22.8%


7-Year Cumulative Returns

-28.2%


5-Year Cumulative Returns

-60.1%


3-Year Cumulative Returns

Risks for NVAX

What is the probability of a big loss on NVAX?

100%


Probability that Novavax stock will be more than 20% underwater in next one year

100%


Probability that Novavax stock will be more than 30% underwater in next one year.

100%


Probability that Novavax stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novavax was unfortunately bought at previous high price.

Drawdowns

Financials for Novavax

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue17.6%1,597,353,0001,358,852,0001,981,872,0001,846,673,0001,290,940,0001,403,032,0001,146,290,0001,203,749,0001,181,929,000919,450,000475,598,000204,755,00050,238,00018,057,00018,662,00015,973,00021,201,00028,617,00034,288,00038,573,00039,190,000
Costs and Expenses-11.9%2,225,732,0002,525,648,0002,626,608,0003,072,501,0002,696,723,0002,671,684,0002,832,866,0002,248,207,0002,113,185,0001,521,904,000892,317,000467,326,000133,854,000121,312,000139,243,000154,361,000186,502,000199,245,000208,206,000213,763,000214,108,000
  S&GA Expenses-2.9%490,788,000505,231,000488,691,000411,242,000366,159,000331,160,000298,358,000275,457,000254,543,000199,101,000145,290,00092,158,00043,178,00035,065,00034,417,00035,461,00035,871,00034,489,00034,409,00033,725,00033,534,000
  R&D Expenses-6.4%1,028,723,0001,098,896,0001,235,278,0001,940,385,0002,044,283,0002,325,320,0002,534,508,0001,972,750,0001,858,642,0001,322,803,000747,027,000375,168,00099,692,00095,263,000113,842,000127,916,000150,631,000164,756,000173,797,000180,038,000180,574,000
EBITDA100.0%--1,101,787,000-604,713,000-1,252,892,000-1,406,213,000-1,249,250,000-1,680,748,000-1,033,103,000-914,745,000-408,196,000-409,632,000-411,276,000-52,755,000-138,663,000-137,649,000------
EBITDA Margin100.0%--0.56-0.31-0.68-1.09-0.89-1.47-0.86-0.77-0.44-0.86-2.01-1.05-7.68-7.38------
Interest Expenses-16.1%16,210,00019,320,00019,880,00020,417,00021,430,00021,164,00021,127,00019,868,00019,146,00016,581,00015,145,00014,669,00013,612,00013,612,00013,612,00013,612,00013,612,00013,612,00013,612,00013,732,00013,849,000
Earnings Before Taxes49.2%-585,507,000-1,152,439,000-653,647,000-1,298,813,000-1,449,062,000-1,288,764,000-1,714,536,000-1,062,425,000-943,345,000-612,097,000-418,259,000-429,662,000-70,084,000--132,694,000------
EBT Margin100.0%--0.58-0.33-0.70-1.12-0.92-1.50-0.88-0.80-0.47-0.90-2.10-1.40-8.69-8.41------
Net Income49.2%-586,759,000-1,155,252,000-657,939,000-1,321,974,000-1,475,792,000-1,317,624,000-1,743,751,000-1,075,031,000-949,910,000-615,114,000-418,259,000-272,525,000-93,258,000-115,340,000-132,694,000-150,198,000-176,725,000-181,614,000-184,748,000-186,257,000-186,294,000
Net Income Margin100.0%--0.58-0.33-0.72-1.14-0.94-1.52-0.89-0.80-0.67-0.88-1.33-1.86-6.39-7.11------
Free Cashflow100.0%--653,027,000-415,937,000-728,573,000--428,649,000322,946,000536,786,000672,432,000643,654,000-42,541,00062,284,00036,522,000-109,126,000-136,623,000-158,146,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets9.2%1,6851,5432,2592,2672,6232,8352,5772,5662,7502,6081,582944932328173165189221208250286
  Current Assets16.1%1,1289711,7031,7602,1362,3472,1552,1742,3552,2471,24867163625597.0089.00110123119161194
    Cash Equivalents-19.0%5066251,3371,2811,3881,5841,5281,9472,1232,02955340253218782.0076.0078.0010682.0075.00100
  Inventory-31.3%23.0034.0037.0082.002561079.00--------------
  Net PPE-2.4%30030729425625524722621521319218013211511.0011.0012.0013.0027.0028.0029.0031.00
  Goodwill-1.1%12813012611812313113113213413113512711950.0051.0050.0051.0051.0052.0052.0052.00
Liabilities0.1%2,4402,4382,8932,8333,0402,7702,9282,1052,0041,569955638548352359355375372376377374
  Current Liabilities-16.8%1,5961,9192,4601,6682,1562,2612,3901,7531,6521,20958023921319.0026.0022.0041.0031.0046.0047.0043.00
Shareholder's Equity15.8%-754-895-634--41665.00-3514617461,039627106185--------
  Retained Earnings1.3%-4,511-4,569-4,275-4,093-3,925-3,414-3,617-2,771-2,449-2,096-1,874-1,696-1,499-1,457-1,431-1,399-1,381-1,342-1,299-1,249-1,205
  Additional Paid-In Capital2.3%3,8563,7683,7383,6413,6053,5663,3523,3113,2373,1802,5351,8491,6991,4501,2611,2261,2111,2021,1451,1331,127
Shares Outstanding9.3%94.0086.0086.0078.0078.0076.0076.0075.0074.0073.0071.0062.0059.0044.0032.0023.0023.0020.0018.0018.0019.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-0.2%-654-653-415-640-743-428323537672644-42.5462.0037.00-109-136-158-159-169-184-182-193
  Share Based Compensation-14.1%10812613013514816318420222217712882.0019.0015.0017.0017.0019.0019.0018.0021.0021.00
Cashflow From Investing16.8%-82.92-99.72-92.98-87.28-69.96-58.2810085.00-3.12-178-377-346-228-37.9538.0087.0077.0027.0029.00-2.9631.00
Cashflow From Financing29.9%-132-18932573.0088.0045.004629279201,37698561064522898.0072.0061.00115103116139

NVAX Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Revenues$ 424,426$ 185,925$ 505,377$ 889,896
Expenses:    
Cost of sales55,777271,07789,863286,281
Research and development219,475289,648466,576673,131
Selling, general, and administrative93,717108,160206,249204,152
Total expenses368,969668,885762,6881,163,564
Income (Loss) from operations55,457(482,960)(257,311)(273,668)
Other income (expense):    
Interest expense(3,124)(6,234)(7,440)(11,110)
Other income (expense)5,532(19,873)29,894(18,219)
Income (Loss) before income tax expense (benefit)57,865(509,067)(234,857)(302,997)
Income tax expense (benefit)(143)1,4181,0404,080
Net income (loss)$ 58,008$ (510,485)$ (235,897)$ (307,077)
Earnings Per Share [Abstract]    
Basic (in usd per share)$ 0.65$ (6.53)$ (2.69)$ (3.97)
Diluted (in usd per share)$ 0.58$ (6.53)$ (2.69)$ (3.97)
​Weighted average number of common shares outstanding    
Basic (in shares)89,36278,14387,76977,305
Diluted (in shares)104,06578,14387,76977,305
Product sales    
Revenue:    
Revenues$ 285,163$ 55,455$ 277,706$ 641,083
Grants    
Revenue:    
Revenues137,079107,774224,458207,075
Royalties and other    
Revenue:    
Revenues$ 2,184$ 22,696$ 3,213$ 41,738

NVAX Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 505,912$ 1,336,883
Restricted cash10,36110,303
Accounts receivable394,89082,375
Inventory23,48836,683
Prepaid expenses and other current assets192,903237,147
Total current assets1,127,5541,703,391
Property and equipment, net299,955294,247
Right of use asset, net95,739106,241
Goodwill128,366126,331
Other non-current assets33,43428,469
Total assets1,685,0482,258,679
Current liabilities:  
Accounts payable87,246216,517
Accrued expenses458,397591,158
Deferred revenue300,473370,137
Current portion of finance lease liabilities95327,196
Convertible notes payable0324,881
Other current liabilities749,186930,055
Total current liabilities1,596,2552,459,944
Deferred revenue606,937179,414
Convertible notes payable167,248166,466
Non-current finance lease liabilities30,74431,238
Other non-current liabilities38,38355,695
Total liabilities2,439,5672,892,757
Commitments and contingencies (Note 15)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022.00
Stockholders' deficit:  
Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 95,183,750 shares issued and 94,308,379 shares outstanding at June 30, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 2022952868
Additional paid-in capital3,855,9163,737,979
Accumulated deficit(4,511,786)(4,275,889)
Treasury stock, cost basis, 875,371 shares at June 30, 2023 and 766,631 shares at December 31, 2022(91,424)(90,659)
Accumulated other comprehensive loss(8,177)(6,377)
Total stockholders’ deficit(754,519)(634,078)
Total liabilities and stockholders’ deficit$ 1,685,048$ 2,258,679

About Novavax